NeuroVive Pharmaceutical AB Interim report January – June 2018
NeuroVive out-licenses targeted LHON therapy to BridgeBioImportant events January-June 2018 · NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma’s new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately $60 million USD including any royalties. · NeuroVive conducts a preferential rights issue. · NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical development. · KL1333 receives FDA Orphan Drug Designation for treatment of mitochondrial diseases. · NeuroVive